PPPippa Powell

Pippa Powell

*This is an algorithmically generated author record based on publicly available information.

Pippa Powell has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    LungHealth4Life (LH4L): Lung function testing, health promotion and disease prevention in schools

    by Judith Garcia-Aymerich, Rosa Faner, Laura Delgado-Ortiz, Pippa Powell

  • Making the case to highlight the burden of respiratory diseases in Europe

    by Guy Joos, Judith Garcia-Aymerich, Silke Ryan, Monika Gappa, Joanna Chorostowska-Wynimko, Marc Humbert, Carlos Robalo Cordeiro, Kjeld Hansen, Anita Simonds, Brian Ward, et al.

    Extract Respiratory diseases continue to represent a major component of morbidity and mortality worldwide. In 2021, in the midst of the COVID-19 pandemic, the International Respiratory Coalition (IRC) was formed between the professional respiratory community (caregivers), people living with respiratory diseases, and industry. The aim of the IRC is to promote lung health and to improve respiratory care – through the vision that every country in Europe should have the tools to implement a national respiratory strategy [1]. Key priority areas were identified as: 1) prevention of respiratory diseases; 2) access to the right treatment at the right time; 3) reducing inequalities; and 4) prioritisation of research, data and insight to improve respiratory care [2]. Shareable abstract Respiratory disease represents a major component of morbidity and mortality. Countries should strive for national respiratory strategies to address this burden. The Lung Facts online resource provides the data needed to advocate for these strategies. https://bit.ly/45xzq98


  • Open Access

    The epidemiological burden and societal cost of 14 respiratory conditions in the WHO European region: systematic evidence map and economic analysis

    by Sue Harnan, Matthew Franklin, Colin Angus, Joan B Soriano, Ane Johannessen, Anthea Sutton, Judith Garcia-Aymerich, Amy Auer, Christopher Carroll, Emma Simpson, et al.

    Introduction: Our systematic evidence map aimed to identify lung-related epidemiological estimates to populate the International Respiratory Coalition's Lung Facts website. We highlight important evidence gaps, suggest how they could be filled, and provide bespoke societal cost estimates to inform resource allocation. Methods: We examined 14 lung conditions across 53 WHO Europe countries, seeking incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life year (DALY) estimates by age/sex. Global Burden of Disease (GBD) study estimates were obtained for 9 GBD-included lung conditions: asthma, chronic obstructive pulmonary disease, interstitial lung disease and pulmonary sarcoidosis, lower respiratory infections, lung cancer/tracheal, bronchus and lung cancer, tuberculosis, mesothelioma, COVID-19 and pulmonary arterial hypertension. Systematic searches of bibliographic databases were necessary for 5 non-GBD-included lung conditions: cystic fibrosis (CF), obstructive sleep apnoea (OSA), influenza, alpha-1 antitrypsin deficiency (A1AD), and bronchiectasis. All-age country-specific DALY estimates were multiplied by Gross Domestic Product (GDP) per capita as a proxy for a country's wealth and prosperity to estimate societal costs. Results: Complete data for 9 lung conditions for all countries were extracted from GBD, enabling societal cost estimation. Significant gaps were found for A1AD (only prevalence for 24 countries) and bronchiectasis (incidence, prevalence, and mortality for 1 to 5 countries), with more but incomplete estimates for CF, OSA, and influenza. Conclusions: More epidemiological evidence is required for A1AD, bronchiectasis, CF, OSA, and influenza. Inclusion in the GDB study could help address these gaps. Lung Facts provides comprehensive lung-related epidemiological and societal cost estimates covering 53 countries to support policy makers advocating for respiratory interventions.


  • Open Access

    Lung Facts: a practical tool to strengthen respiratory advocacy in Europe

    by Guy Joos, Amy Auer, Pippa Powell, Lauren Anderson, Joan B. Soriano, Jana De Brandt, Chantal Raherison Semjen, Bruno Balbi, Aleksander Kania

    Respiratory diseases remain a leading health burden across Europe, yet national strategies are often fragmented or absent. The International Respiratory Coalition's Lung Facts platform offers a comprehensive, up-to-date resource for epidemiological and economic data for major respiratory conditions across 53 European countries. This viewpoint outlines the platform's development and the types of data available, including disease burden, societal costs and risk factor attribution. It also demonstrates how national coalitions are using it to advocate for respiratory health policies. By providing accessible, country-specific information in visual formats, Lung Facts supports benchmarking, evidence-based advocacy and planning of national respiratory strategies. The platform is a dynamic tool intended to strengthen respiratory health policy and empower stakeholders to act on the growing burden of lung disease.

  • Top Cited Papers

    Genetic and environmental risk factors for asthma: towards prevention

    by Gerard H Koppelman, Maria Pino-Yanes, Erik Melén, Pippa Powell, Ken R Bracke, Juan C Celedón, Guy G Brusselle


  • Open Access

    Impact of Digital Health on Patient-Provider Relationships in Respiratory Secondary Care Based on Qualitative and Quantitative Evidence: Systematic Review

    by Michaela Senek, David Drummond, Hilary Pinnock, Kjeld Hansen, Anshu Ankolekar, Úna O'Connor, Apolline Gonsard, Oleksandr Mazulov, Katherina Bernadette Sreter, Christina Thornton, et al.

    Background: Digital health technology adoption has accelerated in respiratory care, particularly since the COVID-19 pandemic, supporting various applications from self-management to telerehabilitation. While these technologies have transformed health care delivery, their impact on the patient-provider relationship in specialist respiratory care remains poorly understood. Objective: This study aims to systematically review the literature on the impact of digital health technology on the patient-provider relationship in respiratory secondary care settings and to understand the factors that enhance or diminish this relationship. Methods: In December 2023, we conducted a systematic review following Cochrane methodology, searching MEDLINE, Embase, CINAHL, Cochrane databases, and PsycINFO. We included qualitative, quantitative, and mixed methods studies examining digital health interventions in respiratory secondary care. Trained volunteers from the European Respiratory Society CONNECT Clinical Research Collaboration performed screening and data extraction. We conducted a qualitative meta-synthesis of findings, followed by an abductive quantitative data analysis. A total of 3 stakeholder workshops were held to interpret findings collaboratively with patients and health care professionals. Results: From 15,779 papers screened, 97 met the inclusion criteria (55 qualitative/mixed-methods studies, 42 quantitative studies). Studies covered various respiratory conditions, including COPD (32%), asthma (26%), and COVID-19 (13%). Four main themes emerged: trust (foundational to the relationship), adoption factors (including clinical context and implementation drivers), confidence in technology (based on functionality and the evidence base), and connection (encompassing communication and a caring presence). Digital health technology can either enhance or diminish trust between patients and clinicians, with patients' perceptions of the motivations behind its implementation being crucial. While technology facilitated access and communication, remote consultations risked depersonalisation, particularly when not balanced with in-person interactions. Self-monitoring and access to information empowered patients and promoted more equitable patient-provider relationships. Conclusions: Digital health technology can either strengthen or weaken patient-provider relationships in respiratory care, with effects impacted by adoption factors, confidence in technology, connection, and patient empowerment. Maintaining trust in the era of digital care requires transparent implementation of motivations, consideration of individual circumstances, and reliable technology that supports rather than replaces the therapeutic relationship. Trial Registration: PROSPERO CRD42024493664; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024493664


  • Open Access

    Impact of Digital Health on Patient-Provider Relationships in Respiratory Secondary Care Based on Qualitative and Quantitative Evidence: Systematic Review (Preprint)

    by Michaela Senek, David Drummond, Hilary Pinnock, Kjeld Hansen, Anshu Ankolekar, Úna O'Connor, Apolline Gonsard, Oleksandr Mazulov, Katherina Bernadette Sreter, Christina Thornton, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Digital health technology adoption has accelerated in respiratory care, particularly since the COVID-19 pandemic, supporting various applications from self-management to telerehabilitation. While these technologies have transformed health care delivery, their impact on the patient-provider relationship in specialist respiratory care remains poorly understood. Objective: This study aims to systematically review the literature on the impact of digital health technology on the patient-provider relationship in respiratory secondary care settings and to understand the factors that enhance or diminish this relationship. Methods: In December 2023, we conducted a systematic review following Cochrane methodology, searching MEDLINE, Embase, CINAHL, Cochrane databases, and PsycINFO. We included qualitative, quantitative, and mixed methods studies examining digital health interventions in respiratory secondary care. Trained volunteers from the European Respiratory Society CONNECT Clinical Research Collaboration performed screening and data extraction. We conducted a qualitative meta-synthesis of findings, followed by an abductive quantitative data analysis. A total of 3 stakeholder workshops were held to interpret findings collaboratively with patients and health care professionals. Results: From 15,779 papers screened, 97 met the inclusion criteria (55 qualitative/mixed-methods studies, 42 quantitative studies). Studies covered various respiratory conditions, including COPD (32%), asthma (26%), and COVID-19 (13%). Four main themes emerged: trust (foundational to the relationship), adoption factors (including clinical context and implementation drivers), confidence in technology (based on functionality and the evidence base), and connection (encompassing communication and a caring presence). Digital health technology can either enhance or diminish trust between patients and clinicians, with patients' perceptions of the motivations behind its implementation being crucial. While technology facilitated access and communication, remote consultations risked depersonalisation, particularly when not balanced with in-person interactions. Self-monitoring and access to information empowered patients and promoted more equitable patient-provider relationships. Conclusions: Digital health technology can either strengthen or weaken patient-provider relationships in respiratory care, with effects impacted by adoption factors, confidence in technology, connection, and patient empowerment. Maintaining trust in the era of digital care requires transparent implementation of motivations, consideration of individual circumstances, and reliable technology that supports rather than replaces the therapeutic relationship. Trial Registration: PROSPERO CRD42024493664; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024493664

  • Healthy lungs for life for schools – developing an early life intervention to prevent chronic adult lung disease (a CADSET pilot project)

    by Pippa Powell, Jessica Denning, Paola Pierucci

    Background: The origins of many chronic adult lung diseases are influenced by lifestyle in childhood. Therefore, there is a need for early interventions that focus on positive life choices to improve lung health from an early age. Aim: To develop an engaging early years intervention to teach young people about the importance of lung health, influence their behaviours and prevent respiratory disease later in life. Methods: An MDT steering group was formed by the European Lung Foundation and ERS CRC CADSET. A two-tiered approach was offered to schools in Barcelona, Spain (to coincide with the ERS Congress) via an online schools forum: tier 1 and 2 providing age-appropriate resources; tier 2 providing nurses to deliver the sessions. A short qualitative survey was provided to measure impact of the sessions. Results: Nine schools took initial interest, two were available for the pilot, both chose tier 2. 14 resources were produced in English, Spanish and Catalan, in-line with the school curriculum and CADSET messaging. Three 1-hour sessions took place with children aged 9-10 years, with 25-50 children per class. Feedback indicated that information should be more detailed and sessions longer. Children were engaged, enjoyed having the nurses teach them and asked complex questions. General written feedback was provided by the schools. Conclusion: A school-based intervention for lung health is feasible and was well received by children and teachers. Resources should be in-depth and longer than 1 hour to allow for practical activities. Formal feedback from the sessions should be collected by the research team to ensure quality.


  • Open Access

    Principles of patient partnership: integrating patient perspectives into ERS Clinical Research Collaborations

    by Courtney Coleman, Olivia Fulton, Jeanette Boyd, Clare Williams, Zena Powell, Christopher E. Brightling, Maarten van Den Berge, Salman Siddiqui, Pippa Powell

    Patient and public involvement in research is increasingly considered a cornerstone of good research practice, and the research community recognises people with lived experience as valuable stakeholders within the research process. European Respiratory Society (ERS) strongly encourages patient input into its research programme and scientific activities, working in partnership with the European Lung Foundation (ELF) to facilitate this. Based on the ERS and ELF experience and best practice in the field of patient and public involvement, we developed a set of principles to which future ERS and ELF collaborations should adhere. These principles provide guidance on how to address key challenges when planning and conducting patient and public involvement in order to develop successful partnerships with patients and drive forward patient-centred research.


  • Open Access

    Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions

    by Sadia Janjua, Pippa Powell, Richard Atkinson, Elizabeth Stovold, Rebecca Fortescue

    Background More than 90% of the global population lives in areas exceeding World Health Organization air quality limits. More than four million people each year are thought to die early due to air pollution, and poor air quality is thought to reduce an average European's life expectancy by one year. Individuals may be able to reduce health risks through interventions such as masks, behavioural changes and use of air quality alerts. To date, evidence is lacking about the efficacy and safety of such interventions for the general population and people with long‐term respiratory conditions. This topic, and the review question relating to supporting evidence to avoid or lessen the effects of air pollution, emerged directly from a group of people with chronic obstructive pulmonary disease (COPD) in South London, UK. Objectives 1. To assess the efficacy, safety and acceptability of individual‐level interventions that aim to help people with or without chronic respiratory conditions to reduce their exposure to outdoor air pollution. 2. To assess the efficacy, safety and acceptability of individual‐level interventions that aim to help people with chronic respiratory conditions reduce the personal impact of outdoor air pollution and improve health outcomes. Search methods We identified studies from the Cochrane Airways Trials Register, Cochrane Central Register of Controlled Trials, and other major databases. We did not restrict our searches by date, language or publication type and included a search of the grey literature (e.g. unpublished information). We conducted the most recent search on 16 October 2020. Selection criteria We included randomised controlled trials (RCTs) and non‐randomised studies (NRS) that included a comparison treatment arm, in adults and children that investigated the effectiveness of an individual‐level intervention to reduce risks of outdoor air pollution. We included studies in healthy individuals and those in people with long‐term respiratory conditions. We excluded studies which focused on non‐respiratory long‐term conditions, such as cardiovascular disease. We did not restrict eligibility of studies based on outcomes. Data collection and analysis We used standard Cochrane methods. Two review authors independently selected trials for inclusion, extracted study characteristics and outcome data, and assessed risk of bias using the Cochrane Risk of Bias tool for RCTs and the Risk Of Bias In Non‐randomised Studies ‐ of Interventions (ROBINS‐I) as appropriate. One review author entered data into the review; this was spot‐checked by a second author. We planned to meta‐analyse results from RCTs and NRS separately, using a random‐effects model. This was not possible, so we presented evidence narratively. We assessed certainty of the evidence using the GRADE approach. Primary outcomes were: measures of air pollution exposure; exacerbation of respiratory conditions; hospital admissions; quality of life; and serious adverse events. Main results We identified 11 studies (3372 participants) meeting our inclusion criteria (10 RCTs and one NRS). Participants’ ages ranged from 18 to 74 years, and the duration of studies ranged from 24 hours to 104 weeks. Six cross‐over studies recruited healthy adults and five parallel studies included either people with pre‐existing conditions (three studies) or only pregnant women (two studies). Interventions included masks (e.g. an N95 mask designed to filter out airborne particles) (five studies), an alternative cycle route (one study), air quality alerts and education (five studies). Studies were set in Australia, China, Iran, the UK, and the USA. Due to the diversity of study designs, populations, interventions and outcomes, we did not perform any meta‐analyses and instead summarised results narratively. We judged both RCTs and the NRS to be at risk of bias from lack of blinding and lack of clarity regarding selection methods. Many studies did not provide a prepublished protocol or trial registration. From five studies (184 participants), we found that masks or altered cycle routes may have little or no impact on physiological markers of air pollution exposure (e.g. blood pressure and heart rate variability), but we are very uncertain about this estimate using the GRADE approach. We found conflicting evidence regarding health care usage from three studies of air pollution alerts, with one non‐randomised cross‐over trial (35 participants) reporting an increase in emergency hospital attendances and admissions, but the other two randomised parallel trials (1553 participants) reporting little to no difference. We also gave the evidence for this outcome a very uncertain GRADE rating. None of our included trials reported respiratory exacerbations, quality of life or serious adverse events. Secondary outcomes were not well reported, but indicated inconsistent impacts of air quality alerts and education interventions on adherence, with some trials reporting improvements in the intervention groups and others reporting little or no difference. Symptoms were reported by three trials, with one randomised cross‐over trial (15 participants) reporting a small increase in breathing difficulties associated with the mask intervention, one non‐randomised cross‐over trial (35 participants) reporting reduced throat and nasal irritation in the lower‐pollution cycle route group (but no clear difference in other respiratory symptoms), and another randomised parallel trial (519 participants) reporting no clear difference in symptoms between those who received a smog warning and those who did not. Authors' conclusions The lack of evidence and study diversity has limited the conclusions of this review. Using a mask or a lower‐pollution cycle route may mitigate some of the physiological impacts from air pollution, but...